neostigmine has been researched along with Autosomal Dominant Myotubular Myopathy in 1 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martin-Flores, M | 1 |
| Paré, MD | 1 |
| Campoy, L | 1 |
| Gleed, RD | 1 |
1 other study available for neostigmine and Autosomal Dominant Myotubular Myopathy
| Article | Year |
|---|---|
Neuromuscular blocking effects of cisatracurium and its antagonism with neostigmine in a canine model of autosomal-recessive centronuclear myopathy.
Topics: Anesthesia Recovery Period; Anesthesia, General; Animals; Atracurium; Cholinesterase Inhibitors; Dis | 2015 |